MedTrace Logo

Observational Study to Evaluate the Safety and Efficacy of NovoMix® 70 in Type 2 Diabetes

NCT00704223 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 619

Last updated 2014-06-24

No results posted yet for this study

Summary

This study is conducted in Europe. The aim of this observational study is to evaluate the incidence of adverse events while using NovoMix® 70 under normal clinical practice conditions in Austria.

Conditions

Interventions

DRUG

biphasic insulin aspart

Start dose and frequency to prescribed by the physician as a result of a normal clinical evaluation

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00704223 on ClinicalTrials.gov